公开(公告)号：US20190038744A1

公开(公告)日：2019-02-07

申请号：US15900369

申请日：2018-02-20

Applicant: Biogen MA Inc.

Inventor： Diego Cadavid ,  Sha Mi

IPC: A61K39/395 ,  A61K38/21 ,  A61B5/11 ,  A61B5/00 ,  A61B3/00 ,  C07K16/28 ,  G01R33/48

Abstract: Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments, the methods and compositions described herein include a reparative agent (e.g., a LINGO-1 antagonist) and an immunomodulatory agent, in combination. Thus, methods, compositions and kits described herein can be useful for treating a CNS demyelinating disease.

公开(公告)号：US20180369215A1

公开(公告)日：2018-12-27

申请号：US16020696

申请日：2018-06-27

Applicant: BIOGEN MA INC.

Inventor： Jermaine Thomas ,  Sha Mi ,  Edward Yin-Shiang Lin ,  Guo Zhu Zheng ,  Bin Ma ,  Richard D. Caldwell ,  Kevin M. Guckian ,  Gnanasambandam Kumaravel

IPC: A61K31/445 ,  A61K31/517 ,  C07D211/34 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/55 ,  A61K31/225 ,  A61K31/695 ,  C07K16/28 ,  A61K38/21 ,  A61K39/395 ,  C07D215/20 ,  C07D405/12 ,  C07D401/06 ,  C07D211/62 ,  C07D211/60

CPC classification number: A61K31/445 ,  A61K31/225 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/517 ,  A61K31/55 ,  A61K31/695 ,  A61K38/21 ,  A61K39/3955 ,  C07D211/34 ,  C07D211/60 ,  C07D211/62 ,  C07D215/20 ,  C07D401/06 ,  C07D405/12 ,  C07K16/2842

Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

公开(公告)号：US09808449B2

公开(公告)日：2017-11-07

申请号：US14757822

申请日：2015-12-23

Applicant: Biogen MA Inc.

Inventor： Jermaine Thomas ,  Sha Mi ,  Edward Yin-Shiang Lin ,  Guo Zhu Zheng ,  Bin Ma ,  Richard D. Caldwell ,  Kevin Guckian ,  Gnanasambandam Kumaravel

IPC: A61K31/445 ,  A61K38/21 ,  A61K31/225 ,  A61K39/395 ,  A61K31/517 ,  A61K31/695 ,  A61K31/4545 ,  C07K16/28 ,  A61K31/4709 ,  C07D215/20 ,  C07D405/12 ,  C07D211/34 ,  C07D211/60 ,  C07D211/62 ,  C07D401/06 ,  A61K31/498 ,  A61K31/55

CPC classification number: A61K31/445 ,  A61K31/225 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/498 ,  A61K31/517 ,  A61K31/55 ,  A61K31/695 ,  A61K38/21 ,  A61K39/3955 ,  C07D211/34 ,  C07D211/60 ,  C07D211/62 ,  C07D215/20 ,  C07D401/06 ,  C07D405/12 ,  C07K16/2842

Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

公开(公告)号：US09796780B2

公开(公告)日：2017-10-24

申请号：US14401002

申请日：2013-05-14

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky

IPC: A61K38/00 ,  A61K38/40 ,  C07K16/28 ,  C07K14/47 ,  C07K14/705

CPC classification number: C07K16/2803 ,  C07K14/4705 ,  C07K14/70503 ,  C07K2317/76 ,  C07K2319/30

Abstract: The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist. An exemplary method for promoting survival of a motor neuron, comprising contacting said motor neuron with an effective amount of a composition comprising a LINGO-2 antagonist selected from the group consisting of: (i) a soluble LINGO-2 polypeptide; (ii) a LINGO-2 antibody or antigen-binding fragment thereof; (iii) a LINGO-2 antagonist polynucleotide; (iv) a LINGO-2 aptamer; and (v) a combination of two or more of said LINGO-2 antagonists.

公开(公告)号：US20170037126A1

公开(公告)日：2017-02-09

申请号：US15214818

申请日：2016-07-20

Applicant: Biogen MA Inc.

Inventor： Sha Mi ,  R. Blake Pepinsky ,  Zhaohui Shao ,  Ellen A. Garber Stark ,  Steven D. Miklasz ,  Christilyn Graff

IPC: C07K16/28

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性Sp35功能的分子，这种抗Sp35抗体可以用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对Sp35特异性的抗体，以及使用抗体作为内源性Sp35功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。

公开(公告)号：US20160354465A1

公开(公告)日：2016-12-08

申请号：US15155399

申请日：2016-05-16

Applicant: Biogen MA Inc.

Inventor： Sha Mi

IPC: A61K39/395 ,  C07K14/705 ,  A61K9/00 ,  C07K16/28 ,  A61K31/7088 ,  A61K38/17

CPC classification number: A61K39/3955 ,  A61K9/0048 ,  A61K31/00 ,  A61K31/7088 ,  A61K38/17 ,  A61K38/185 ,  A61K2039/505 ,  C07K14/705 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/76 ,  C07K2319/30 ,  A61K2300/00

Abstract: This invention relates to methods for promoting neuronal survival and regeneration using LINGO-1 antagonists and TrkB agonists. Additionally, the invention relates to methods for treating pressure induced optic neuropathies using LINGO-1 antagonists. The invention also relates generally to methods for increasing TrkB activity and inhibiting JNK pathway signaling using a LINGO-1 antagonist.

Abstract translation: 本发明涉及使用LINGO-1拮抗剂和TrkB激动剂促进神经元存活和再生的方法。 此外，本发明涉及使用LINGO-1拮抗剂治疗压力诱导的视神经病变的方法。 本发明一般还涉及使用LINGO-1拮抗剂增加TrkB活性和抑制JNK途径信号转导的方法。